Regents Of University Of California

General

Total Cases133

Active Cases19

Patents8,899

CourtsN.D. California C.D. California D. Delaware

TypeNPE

Elite Ratings

PTAB

regents.universityofcalifornia.edu

university-of-california

Ratings

Experience

Grade

Trend

DCT

L3

A

PTAB

L5

A

CAFC

L3

E

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered	Case	Description
09/06/24	Evolve Biosystems Inc v. Abbott Laboratories 1:19-CV-05859 ( N.D. IL )	MOTION by Plaintiffs Evolve BioSystems, Inc., Regents of the University of California to seal Unopposed Motion for Leave to File Under Seal Portions of Omnibus Memorandum in Support of Cross-Motion for Summary Judgment and Motion to Exclude Expert Testimony, LR 56.1 Statement, and Exhibits to the Declaration of Soo J. Park Presented before District Judge (Chivvis, Matthew) (Entered: 09/06/2024)
09/06/24	Evolve Biosystems Inc v. Abbott Laboratories 1:19-CV-05859 ( N.D. IL )	SEALED MOTION by Plaintiffs Evolve BioSystems, Inc., Regents of the University of California Omnibus Memorandum in Support of Cross-Motion for Summary Judgment and Motion to Exclude Expert Testimony and In Response to Abbott's Memorandum in Support of Its Motion for Summary Judgment and Motion to Exclude Expert Testimony (Unredacted) Presented before District Judge (Attachments: # 1 Omnibus LR 56.1 Statement of Material Facts (Unredacted), # 2 Exhibit 3 (Unredacted), # 3 Exhibit 4 (Unredacted), # 4 Exhibit 5 (Unredacted), # 5 Exhibit 7 (Unredacted), # 6 Exhibit 13 (Unredacted), # 7 Exhibit 14 (Unredacted), # 8 Exhibit 15 (Unredacted), # 9 Exhibit 16 (Unredacted), # 10 Exhibit 17 (Unredacted), # 11 Exhibit 19 (Unredacted), # 12 Exhibit 20 (Unredacted), # 13 Exhibit 21 (Unredacted), # 14 Exhibit 22 (Unredacted), # 15 Exhibit 23 (Unredacted), # 16 Exhibit 24 (Unredacted), # 17 Exhibit 25 (Unredacted), # 18 Exhibit 26 (Unredacted), # 19 Exhibit 27 (Unredacted), # 20 Exhibit 29 (Unredacted), # 21 Exhibit 30 (Unredacted), # 22 Exhibit 31 (Unredacted), # 23 Exhibit 32 (Unredacted), # 24 Exhibit 33 (Unredacted), # 25 Exhibit 34 (Unredacted), # 26 Exhibit 35 (Unredacted), # 27 Exhibit 36 (Unredacted), # 28 Exhibit 37 (Unredacted), # 29 Exhibit 38 (Unredacted), # 30 Exhibit 39 (Unredacted), # 31 Exhibit 40 (Unredacted), # 32 Exhibit 42 (Unredacted), # 33 Exhibit 43 (Unredacted), # 34 Exhibit 44 (Unredacted), # 35 Exhibit 46 (Unredacted), # 36 Exhibit 47 (Unredacted), # 37 Exhibit 48 (Unredacted), # 38 Exhibit 49 (Unredacted), # 39 Exhibit 50 (Unredacted), # 40 Exhibit 51 (Unredacted), # 41 Exhibit 60 (Unredacted), # 42 Exhibit 61 (Unredacted), # 43 Exhibit 62 (Unredacted), # 44 Exhibit 63 - Part 1 (Unredacted), # 45 Exhibit 63 - Part 2 (Unredacted), # 46 Exhibit 63 - Part 3 (Unredacted), # 47 Exhibit 65 (Unredacted), # 48 Exhibit 66 (Unredacted), # 49 Exhibit 67 (Unredacted), # 50 Exhibit 68 (Unredacted), # 51 Exhibit 69 (Unredacted), # 52 Exhibit 70 (Unredacted), # 53 Exhibit 74 (Unredacted), # 54 Exhibit 75 (Unredacted), # 55 Exhibit 81 (Unredacted), # 56 Exhibit 82 (Unredacted), # 57 Exhibit 86 (Unredacted), # 58 Exhibit 87 (Unredacted), # 59 Exhibit 88 (Unredacted), # 60 Exhibit 89 - Part 1 (Unredacted), # 61 Exhibit 89 - Part 2 (Unredacted), # 62 Exhibit 91 (Unredacted), # 63 Exhibit 92 (Unredacted), # 64 Exhibit 94 (Unredacted), # 65 Exhibit 95 (Unredacted), # 66 Exhibit 96 (Unredacted), # 67 Exhibit 97 (Unredacted), # 68 Exhibit 98 (Unredacted), # 69 Exhibit 99 (Unredacted))(Chivvis, Matthew) (Entered: 09/06/2024) SEALED MOTION by Plaintiffs Evolve BioSystems, Inc., Regents of the University of California Omnibus Memorandum in Support of Cross-Motion for Summary Judgment and Motion to Exclude Expert Testimony and In Response to Abbott's Memorandum in Support of Its Motion for Summary Judgment and Motion to Exclude Expert Testimony (Unredacted) Presented before District Judge (Attachments: # 1 Omnibus LR 56.1 Statement of Material Facts (Unredacted), # 2 Exhibit 3 (Unredacted), # 3 Exhibit 4 (Unredacted), # 4 Exhibit 5 (Unredacted), # 5 Exhibit 7 (Unredacted), # 6 Exhibit 13 (Unredacted), # 7 Exhibit 14 (Unredacted), # 8 Exhibit 15 (Unredacted), # 9 Exhibit 16 (Unredacted), # 10 Exhibit 17 (Unredacted), # 11 Exhibit 19 (Unredacted), # 12 Exhibit 20 (Unredacted), # 13 Exhibit 21 (Unredacted), # 14 Exhibit 22 (Unredacted), # 15 Exhibit 23 (Unredacted), # 16 Exhibit 24 (Unredacted), # 17 Exhibit 25 (Unredacted), # 18 Exhibit 26 (Unredacted), # 19 Exhibit 27 (Unredacted), # 20 Exhibit 29 (Unredacted), # 21 Exhibit 30 (Unredacted), # 22 Exhibit 31 (Unredacted), # 23 Exhibit 32 (Unredacted), # 24 Exhibit 33 (Unredacted), # 25 Exhibit 34 (Unredacted), # 26 Exhibit 35 (Unredacted), # 27 Exhibit 36 (Unredacted), # 28 Exhibit 37 (Unredacted), # 29 Exhibit 38 (Unredacted), # 30 Exhibit 39 (Unredacted), # 31 Exhibit 40 (Unredacted), # 32 Exhibit 42 (Unredacted), # 33 Exhibit 43 (Unredacted), # 34 Exhibit 44 (Unredacted), # 35 Exhibit 46 (Unredacted), # 36 Exhibit 47 (Unredacted), # 37 Exhibit 48 (Unredacted), # 38 Exhibit 49 (Unredacted), # 39 Exhibit 50 (Unredacted), # 40 Exhibit 51 (Unredacted), # 41 Exhibit 60 (Unredacted), # 42 Exhibit 61 (Unredacted), # 43 Exhibit 62 (Unredacted), # 44 Exhibit 63 - Part 1 (Unredacted), # 45 Exhibit 63 - Part 2 (Unredacted), # 46 Exhibit 63 - Part 3 (Unredacted), # 47 Exhibit 65 (Unredacted), # 48 Exhibit 66 (Unredacted), # 49 Exhibit 67 (Unredacted), # 50 Exhibit 68 (Unredacted), # 51 Exhibit 69 (Unredacted), # 52 Exhibit 70 (Unredacted), # 53 Exhibit 74 (Unredacted), # 54 Exhibit 75 (Unredacted), # 55 Exhibit 81 (Unredacted), # 56 Exhibit 82 (Unredacted), # 57 Exhibit 86 (Unredacted), # 58 Exhibit 87 (Unredacted), # 59 Exhibit 88 (Unredacted), # 60 Exhibit 89 - Part 1 (Unredacted), # 61 Exhibit 89 - Part 2 (Unredacted), # 62 Exhibit 91 (Unredacted), # 63 Exhibit 92 (Unredacted), # 64 Exhibit 94 (Unredacted), # 65 Exhibit 95 (Unredacted), # 66 Exhibit 96 (Unredacted), # 67 Exhibit 97 (Unredacted), # 68 Exhibit 98 (Unredacted), # 69 Exhibit 99 (Unredacted))(Chivvis, Matthew) (Entered: 09/06/2024)
09/06/24	Evolve Biosystems Inc v. Abbott Laboratories 1:19-CV-05859 ( N.D. IL )	MEMORANDUM by Evolve BioSystems, Inc., Regents of the University of California in support of motion for summary judgment, 399 Omnibus Memorandum in Support of Cross-Motion for Summary Judgment and Motion to Exclude Expert Testimony and In Response to Abbott's Memorandum in Support of Its Motion for Summary Judgment and Motion to Exclude Expert Testimony (Attachments: # 1 Omnibus LR 56.1 Statement of Material Facts, # 2 Declaration of Soo J. Park, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3 (Redacted), # 6 Exhibit 4 (Redacted), # 7 Exhibit 5 (Redacted), # 8 Exhibit 6, # 9 Exhibit 7 (Redacted), # 10 Exhibit 8 (Part 1), # 11 Exhibit 8 (Part 2), # 12 Exhibit 9, # 13 Exhibit 10, # 14 Exhibit 11, # 15 Exhibit 12, # 16 Exhibit 13 (Redacted), # 17 Exhibit 14 (Redacted), # 18 Exhibit 15 (Redacted), # 19 Exhibit 16 (Redacted), # 20 Exhibit 17 (Redacted), # 21 Exhibit 18, # 22 Exhibit 19 (Redacted), # 23 Exhibit 20 (Redacted), # 24 Exhibit 21 (Redacted), # 25 Exhibit 22 (Redacted), # 26 Exhibit 23 (Redacted), # 27 Exhibit 24 (Redacted), # 28 Exhibit 25 (Redacted), # 29 Exhibit 26 (Redacted), # 30 Exhibit 27 (Redacted), # 31 Exhibit 28, # 32 Exhibit 29 (Redacted), # 33 Exhibit 30 (Redacted), # 34 Exhibit 31 (Redacted), # 35 Exhibit 32 (Redacted), # 36 Exhibit 33 (Redacted), # 37 Exhibit 34 (Redacted), # 38 Exhibit 35 (Redacted), # 39 Exhibit 36 (Redacted), # 40 Exhibit 37 (Redacted), # 41 Exhibit 38 (Redacted), # 42 Exhibit 39 (Redacted), # 43 Exhibit 40 (Redacted), # 44 Exhibit 41, # 45 Exhibit 42 (Redacted), # 46 Exhibit 43 (Redacted), # 47 Exhibit 44 (Redacted), # 48 Exhibit 45, # 49 Exhibit 46 (Redacted), # 50 Exhibit 47 (Redacted), # 51 Exhibit 48 (Redacted), # 52 Exhibit 49 (Redacted), # 53 Exhibit 50 (Redacted), # 54 Exhibit 51 (Redacted), # 55 Exhibit 52, # 56 Exhibit 53, # 57 Exhibit 54, # 58 Exhibit 55, # 59 Exhibit 56, # 60 Exhibit 57, # 61 Exhibit 58, # 62 Exhibit 59, # 63 Exhibit 60 (Redacted), # 64 Exhibit 61 (Redacted), # 65 Exhibit 62 (Redacted), # 66 Exhibit 63 (Redacted), # 67 Exhibit 64, # 68 Exhibit 65 (Redacted), # 69 Exhibit 66 (Redacted), # 70 Exhibit 67 (Redacted), # 71 Exhibit 68 (Redacted), # 72 Exhibit 69 (Redacted), # 73 Exhibit 70 (Redacted), # 74 Exhibit 71, # 75 Exhibit 72, # 76 Exhibit 73, # 77 Exhibit 74 (Redacted), # 78 Exhibit 75 (Redacted), # 79 Exhibit 76, # 80 Exhibit 77, # 81 Exhibit 78, # 82 Exhibit 79, # 83 Exhibit 80, # 84 Exhibit 81 (Redacted), # 85 Exhibit 82 (Redacted), # 86 Exhibit 83, # 87 Exhibit 84, # 88 Exhibit 85, # 89 Exhibit 86 (Redacted), # 90 Exhibit 87 (Redacted), # 91 Exhibit 88 (Redacted), # 92 Exhibit 89 (Redacted), # 93 Exhibit 90, # 94 Exhibit 91 (Redacted), # 95 Exhibit 92 (Redacted), # 96 Exhibit 93, # 97 Exhibit 94 (Redacted), # 98 Exhibit 95 (Redacted), # 99 Exhibit 96 (Redacted), # 100 Exhibit 97 (Redacted), # 101 Exhibit 98 (Redacted), # 102 Exhibit 99 (Redacted))(Chivvis, Matthew) (Entered: 09/06/2024) MEMORANDUM by Evolve BioSystems, Inc., Regents of the University of California in support of motion for summary judgment, 399 Omnibus Memorandum in Support of Cross-Motion for Summary Judgment and Motion to Exclude Expert Testimony and In Response to Abbott's Memorandum in Support of Its Motion for Summary Judgment and Motion to Exclude Expert Testimony (Attachments: # 1 Omnibus LR 56.1 Statement of Material Facts, # 2 Declaration of Soo J. Park, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3 (Redacted), # 6 Exhibit 4 (Redacted), # 7 Exhibit 5 (Redacted), # 8 Exhibit 6, # 9 Exhibit 7 (Redacted), # 10 Exhibit 8 (Part 1), # 11 Exhibit 8 (Part 2), # 12 Exhibit 9, # 13 Exhibit 10, # 14 Exhibit 11, # 15 Exhibit 12, # 16 Exhibit 13 (Redacted), # 17 Exhibit 14 (Redacted), # 18 Exhibit 15 (Redacted), # 19 Exhibit 16 (Redacted), # 20 Exhibit 17 (Redacted), # 21 Exhibit 18, # 22 Exhibit 19 (Redacted), # 23 Exhibit 20 (Redacted), # 24 Exhibit 21 (Redacted), # 25 Exhibit 22 (Redacted), # 26 Exhibit 23 (Redacted), # 27 Exhibit 24 (Redacted), # 28 Exhibit 25 (Redacted), # 29 Exhibit 26 (Redacted), # 30 Exhibit 27 (Redacted), # 31 Exhibit 28, # 32 Exhibit 29 (Redacted), # 33 Exhibit 30 (Redacted), # 34 Exhibit 31 (Redacted), # 35 Exhibit 32 (Redacted), # 36 Exhibit 33 (Redacted), # 37 Exhibit 34 (Redacted), # 38 Exhibit 35 (Redacted), # 39 Exhibit 36 (Redacted), # 40 Exhibit 37 (Redacted), # 41 Exhibit 38 (Redacted), # 42 Exhibit 39 (Redacted), # 43 Exhibit 40 (Redacted), # 44 Exhibit 41, # 45 Exhibit 42 (Redacted), # 46 Exhibit 43 (Redacted), # 47 Exhibit 44 (Redacted), # 48 Exhibit 45, # 49 Exhibit 46 (Redacted), # 50 Exhibit 47 (Redacted), # 51 Exhibit 48 (Redacted), # 52 Exhibit 49 (Redacted), # 53 Exhibit 50 (Redacted), # 54 Exhibit 51 (Redacted), # 55 Exhibit 52, # 56 Exhibit 53, # 57 Exhibit 54, # 58 Exhibit 55, # 59 Exhibit 56, # 60 Exhibit 57, # 61 Exhibit 58, # 62 Exhibit 59, # 63 Exhibit 60 (Redacted), # 64 Exhibit 61 (Redacted), # 65 Exhibit 62 (Redacted), # 66 Exhibit 63 (Redacted), # 67 Exhibit 64, # 68 Exhibit 65 (Redacted), # 69 Exhibit 66 (Redacted), # 70 Exhibit 67 (Redacted), # 71 Exhibit 68 (Redacted), # 72 Exhibit 69 (Redacted), # 73 Exhibit 70 (Redacted), # 74 Exhibit 71, # 75 Exhibit 72, # 76 Exhibit 73, # 77 Exhibit 74 (Redacted), # 78 Exhibit 75 (Redacted), # 79 Exhibit 76, # 80 Exhibit 77, # 81 Exhibit 78, # 82 Exhibit 79, # 83 Exhibit 80, # 84 Exhibit 81 (Redacted), # 85 Exhibit 82 (Redacted), # 86 Exhibit 83, # 87 Exhibit 84, # 88 Exhibit 85, # 89 Exhibit 86 (Redacted), # 90 Exhibit 87 (Redacted), # 91 Exhibit 88 (Redacted), # 92 Exhibit 89 (Redacted), # 93 Exhibit 90, # 94 Exhibit 91 (Redacted), # 95 Exhibit 92 (Redacted), # 96 Exhibit 93, # 97 Exhibit 94 (Redacted), # 98 Exhibit 95 (Redacted), # 99 Exhibit 96 (Redacted), # 100 Exhibit 97 (Redacted), # 101 Exhibit 98 (Redacted), # 102 Exhibit 99 (Redacted))(Chivvis, Matthew) (Entered: 09/06/2024)
09/05/24	Evolve Biosystems Inc v. Abbott Laboratories 1:19-CV-05859 ( N.D. IL )	MOTION by Plaintiffs Regents of the University of California, Evolve BioSystems, Inc. for summary judgment Omnibus Cross-Motion for Summary Judgment and Motion to Exclude Expert Testimony Presented before District Judge (Chivvis, Matthew) (Entered: 09/05/2024)
08/30/24	Evolve Biosystems Inc v. Abbott Laboratories 1:19-CV-05859 ( N.D. IL )	OBJECTION by Defendant Abbott Laboratories to report and recommendations,,,, 395 (Attachments: # 1 Declaration of Kevin J. Boyle, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4)(Wickramasekera, Nimalka) (Entered: 08/30/2024)
08/30/24	Evolve Biosystems Inc v. Abbott Laboratories 1:19-CV-05859 ( N.D. IL )	SEALED REPORT AND RECOMMENDATION. Signed by the Honorable Heather K. McShain on 8/30/2024. (pk, ) (Entered: 08/30/2024)
08/30/24	Evolve Biosystems Inc v. Abbott Laboratories 1:19-CV-05859 ( N.D. IL )	MINUTE entry before the Honorable Heather K. McShain: For the reasons stated in the corresponding Report and Recommendation, and in accordance with 28 U.S.C. § 636(b)(1)(B) and Fed. R. Civ. P. 72(b)(1), the undersigned respectfully recommends that the District Judge grant in part and deny in part plaintiffs' motion to strike defendant's expert reports 357 . The parties are advised that any objection to this Report and Recommendation must be filed in writing with the Clerk of the Court within fourteen days after service of a copy of this Report and Recommendation. 28 U.S.C. § 636(b)(1); Fed. R. Civ. P. 72(b)(2). Failure to file a timely objection will constitute a waiver of objections on appeal. See Schur v. L.A. Weight Loss Ctrs., Inc., 577 F.3d 752, 760 (7th Cir. 2009); Lorentzen v. Anderson Pest Control, 64 F.3d 327, 330 (7th Cir. 1995); Video Views, Inc. v. Studio 21, Ltd., 797 F.2d 538, 539 (7th Cir. 1986). Out of an abundance of caution, the Court files this Report and Recommendation under seal until further order of the Court. By 09/06/2024, if necessary the parties are to file with the Court a status report identifying any portion of the Report and Recommendation that should remain sealed. The parties are reminded that "[t]he party seeking to seal items has the burden of showing cause and must 'analyze in detail, document by document, the propriety of secrecy, providing reasons and legal citations.'" Nor v. Alrashid, No. 20 CV 7470, 2023 WL 2771167, at 2 (N.D. Ill. Apr. 4, 2023) (quoting E.E.O.C. v. Abbott Labs., No. 10 CV 833, 2012 WL 2884882, at 1 (E.D. Wis. July 12, 2012)). The Seventh Circuit places a high burden on parties seeking to seal parts of the judicial record, but "narrow, specific requests will be granted when based on articulated, reasonable concerns for confidentiality." KM Enters., Inc. v. Global Traffic Techs., Inc., 725 F.3d 718, 734 (7th Cir. 2013); Baxter Int'l, Inc. v. Abbott Labs., 297 F.3d 544, 548 (7th Cir. 2002). If nothing is filed, the Court will direct the Clerk of the Court to unseal the Report and Recommendation on the docket. Mailed notice. (pk, ) (Entered: 08/30/2024) MINUTE entry before the Honorable Heather K. McShain: For the reasons stated in the corresponding Report and Recommendation, and in accordance with 28 U.S.C. § 636(b)(1)(B) and Fed. R. Civ. P. 72(b)(1), the undersigned respectfully recommends that the District Judge grant in part and deny in part plaintiffs' motion to strike defendant's expert reports 357 . The parties are advised that any objection to this Report and Recommendation must be filed in writing with the Clerk of the Court within fourteen days after service of a copy of this Report and Recommendation. 28 U.S.C. § 636(b)(1); Fed. R. Civ. P. 72(b)(2). Failure to file a timely objection will constitute a waiver of objections on appeal. See Schur v. L.A. Weight Loss Ctrs., Inc., 577 F.3d 752, 760 (7th Cir. 2009); Lorentzen v. Anderson Pest Control, 64 F.3d 327, 330 (7th Cir. 1995); Video Views, Inc. v. Studio 21, Ltd., 797 F.2d 538, 539 (7th Cir. 1986). Out of an abundance of caution, the Court files this Report and Recommendation under seal until further order of the Court. By 09/06/2024, if necessary the parties are to file with the Court a status report identifying any portion of the Report and Recommendation that should remain sealed. The parties are reminded that "[t]he party seeking to seal items has the burden of showing cause and must 'analyze in detail, document by document, the propriety of secrecy, providing reasons and legal citations.'" Nor v. Alrashid, No. 20 CV 7470, 2023 WL 2771167, at 2 (N.D. Ill. Apr. 4, 2023) (quoting E.E.O.C. v. Abbott Labs., No. 10 CV 833, 2012 WL 2884882, at 1 (E.D. Wis. July 12, 2012)). The Seventh Circuit places a high burden on parties seeking to seal parts of the judicial record, but "narrow, specific requests will be granted when based on articulated, reasonable concerns for confidentiality." KM Enters., Inc. v. Global Traffic Techs., Inc., 725 F.3d 718, 734 (7th Cir. 2013); Baxter Int'l, Inc. v. Abbott Labs., 297 F.3d 544, 548 (7th Cir. 2002). If nothing is filed, the Court will direct the Clerk of the Court to unseal the Report and Recommendation on the docket. Mailed notice. (pk, ) (Entered: 08/30/2024)
08/16/24	Evolve Biosystems Inc v. Abbott Laboratories 1:19-CV-05859 ( N.D. IL )	REPORT AND RECOMMENDATION: For the reasons stated in the corresponding Report and Recommendation, and in accordance with 28 U.S.C. § 636(b)(1)(B) and Fed. R. Civ. P. 72(b)(1), the undersigned respectfully recommends that the District Judge deny defendant's motion to strike 353 , as well as defendant's alternative requests to amend its final invalidity contentions or reopen expert discovery. The parties are advised that any objection to this Report and Recommendation must be filed in writing with the Clerk of the Court within fourteen days after service of a copy of this Report and Recommendation. 28 U.S.C. § 636(b)(1); Fed. R. Civ. P. 72(b)(2). Failure to file a timely objection will constitute a waiver of objections on appeal. See Schur v. L.A. Weight Loss Ctrs., Inc., 577 F.3d 752, 760 (7th Cir. 2009); Lorentzen v. Anderson Pest Control, 64 F.3d 327, 330 (7th Cir. 1995); Video Views, Inc. v. Studio 21, Ltd., 797 F.2d 538, 539 (7th Cir. 1986). Signed by the Honorable Heather K. McShain on 8/16/2024. Mailed notice. (pk, ) (Entered: 08/16/2024) REPORT AND RECOMMENDATION: For the reasons stated in the corresponding Report and Recommendation, and in accordance with 28 U.S.C. § 636(b)(1)(B) and Fed. R. Civ. P. 72(b)(1), the undersigned respectfully recommends that the District Judge deny defendant's motion to strike 353 , as well as defendant's alternative requests to amend its final invalidity contentions or reopen expert discovery. The parties are advised that any objection to this Report and Recommendation must be filed in writing with the Clerk of the Court within fourteen days after service of a copy of this Report and Recommendation. 28 U.S.C. § 636(b)(1); Fed. R. Civ. P. 72(b)(2). Failure to file a timely objection will constitute a waiver of objections on appeal. See Schur v. L.A. Weight Loss Ctrs., Inc., 577 F.3d 752, 760 (7th Cir. 2009); Lorentzen v. Anderson Pest Control, 64 F.3d 327, 330 (7th Cir. 1995); Video Views, Inc. v. Studio 21, Ltd., 797 F.2d 538, 539 (7th Cir. 1986). Signed by the Honorable Heather K. McShain on 8/16/2024. Mailed notice. (pk, ) (Entered: 08/16/2024)
08/16/24	Evolve Biosystems Inc v. Abbott Laboratories 1:19-CV-05859 ( N.D. IL )	REPORT AND RECOMMENDATION: For the reasons stated in the corresponding Report and Recommendation, and in accordance with 28 U.S.C. Â§ 636(b)(1)(B) and Fed. R. Civ. P. 72(b)(1), the undersigned respectfully recommends that the District Judge deny defendant's motion to strike 353, as well as defendant's alternative requests to amend its final invalidity contentions or reopen expert discovery. The parties are advised that any objection to this Report and Recommendation must be filed in writing with the Clerk of the Court within fourteen days after service of a copy of this Report and Recommendation. 28 U.S.C. Â§ 636(b)(1); Fed. R. Civ. P. 72(b)(2). Failure to file a timely objection will constitute a waiver of objections on appeal. See Schur v. L.A. Weight Loss Ctrs., Inc., 577 F.3d 752, 760 (7th Cir. 2009); Lorentzen v. Anderson Pest Control, 64 F.3d 327, 330 (7th Cir. 1995); Video Views, Inc. v. Studio 21, Ltd., 797 F.2d 538, 539 (7th Cir. 1986). Signed by the Honorable Heather K. McShain on 8/16/2024. Mailed notice. (pk, ) (Entered: 08/16/2024) REPORT AND RECOMMENDATION: For the reasons stated in the corresponding Report and Recommendation, and in accordance with 28 U.S.C. Â§ 636(b)(1)(B) and Fed. R. Civ. P. 72(b)(1), the undersigned respectfully recommends that the District Judge deny defendant's motion to strike 353, as well as defendant's alternative requests to amend its final invalidity contentions or reopen expert discovery. The parties are advised that any objection to this Report and Recommendation must be filed in writing with the Clerk of the Court within fourteen days after service of a copy of this Report and Recommendation. 28 U.S.C. Â§ 636(b)(1); Fed. R. Civ. P. 72(b)(2). Failure to file a timely objection will constitute a waiver of objections on appeal. See Schur v. L.A. Weight Loss Ctrs., Inc., 577 F.3d 752, 760 (7th Cir. 2009); Lorentzen v. Anderson Pest Control, 64 F.3d 327, 330 (7th Cir. 1995); Video Views, Inc. v. Studio 21, Ltd., 797 F.2d 538, 539 (7th Cir. 1986). Signed by the Honorable Heather K. McShain on 8/16/2024. Mailed notice. (pk, ) (Entered: 08/16/2024)
08/05/24	Aragon Pharmaceuticals Inc v. Hetero Labs Ltd Unit V 2:22-CV-03212 ( D. NJ )	Minute Entry for proceedings held before Magistrate Judge Leda D. Wettre: Status Conference held on 8/5/2024. (LM, ) (Entered: 08/05/2024)